Dr. Reddy’s Laboratories (NYSE:RDY) Announces Quarterly Earnings Results

Dr. Reddy’s Laboratories (NYSE:RDY) announced its quarterly earnings results on Friday. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03, FiscalAI reports. Dr. Reddy’s Laboratories had a return on equity of 9.49% and a net margin of 10.15%. The firm had revenue of $903.89 million for the quarter, compared to analyst estimates of $892.16 million.

Here are the key takeaways from Dr. Reddy’s Laboratories’ conference call:

• Revenue declined 1.5% year over year to INR 8,671 crore, primarily reflecting lower North American lenalidomide sales. EBITDA margin fell to 20.6% year over year, while higher freight, personnel and raw-material costs also weighed on profitability.
• The underlying business excluding lenalidomide delivered double-digit growth, supported by new product launches and productivity measures. Management expects gross margins to remain within the 50%-55% range and reiterated its ambition to move EBITDA margins toward 25% over time.
• Semaglutide supply is expected to resume in November 2026, subject to completion of validation, with API already shipped to the fill-and-finish partner. Management remains confident in its previously indicated 6-7 million device volume for the year and is preparing for a potential 12-15 million pen run rate over the following 12 months.
• India and emerging markets remained strong, growing 17% and 24% year over year, respectively, while North America’s base business also posted double-digit growth excluding lenalidomide. The company launched multiple products, including sugammadex in the U.S., and continues to expand its biosimilar and complex-generic pipeline.
• Abatacept remains targeted for U.S. approval by December 22, 2026, although management acknowledged the possibility of a CRL; commercial ramp-up may take roughly six months after approval. Europe and PSAI remained weak due to price erosion, operating-model changes and lower API volumes, although the CDMO business grew and management expects it to reach two to three times current revenue in three to four years.

Dr. Reddy’s Laboratories Trading Up 0.0%

Shares of NYSE:RDY traded up $0.00 during midday trading on Friday, reaching $13.23. The company’s stock had a trading volume of 1,775,415 shares, compared to its average volume of 2,522,937. Dr. Reddy’s Laboratories has a fifty-two week low of $11.36 and a fifty-two week high of $15.67. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.39 and a current ratio of 1.90. The firm has a 50 day moving average price of $12.34 and a two-hundred day moving average price of $12.91. The firm has a market capitalization of $11.04 billion, a price-to-earnings ratio of 30.03, a PEG ratio of 2.75 and a beta of 0.29.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on RDY shares. Weiss Ratings restated a “hold (c-)” rating on shares of Dr. Reddy’s Laboratories in a report on Wednesday. Citigroup upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “buy” rating and raised their price objective for the company from $1,040.00 to $1,450.00 in a report on Tuesday, September 29th. BNP Paribas Exane upgraded shares of Dr. Reddy’s Laboratories to an “outperform” rating and set a $14.80 price objective for the company in a report on Monday, October 12th. Finally, Wall Street Zen upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, October 17th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $732.40.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a global pharmaceutical company headquartered in Hyderabad, India. Founded in 1984 by Dr. Kallam Anji Reddy, the company develops, manufactures and markets medicines intended to make healthcare more accessible.

Its business includes generic prescription drugs, active pharmaceutical ingredients, biosimilars, specialty products and over-the-counter consumer healthcare products. Dr. Reddy’s offers medicines across therapeutic areas such as cardiovascular care, diabetes, oncology, gastrointestinal health, pain management and dermatology.

The company serves patients and healthcare providers in India, the United States, Europe and a range of other international markets, including emerging markets.